Cited by 82Cancer, Hypoxia, and MetabolismAmino Acid Enzymes and MetabolismCancer, Lipids, and Metabolism

Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth

Open access
Chen, Jinyun, Chung, Franklin, Yang, Guizhi, Pu, Minying, Gao, Hui, Jiang, Wei, Yin, Hong, Capka, Vladimir +6 more·2013·Oncotarget

Abstract

// Jinyun Chen 1 , Franklin Chung 1 , Guizhi Yang 1 , Minying Pu 1 , Hui Gao 1 , Wei Jiang 2 , Hong Yin 2 , Vladimir Capka 2 , Shailaja Kasibhatla 3 , Bryan Laffitte 3 , Savina Jaeger 1 , Raymond Pagliarini 1 , Yaoyu Chen 1 and Wenlai Zhou 1 1 Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States 2 Analytic Science, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States 3 The Genomics Institute of the Novartis Research Foundation, San Diego, California, United States Correspondence: Yaoyu Chen, email : yaoyu.chen@novartis.com, email: // Wenlai Zhou, email: // Keywords : PHGDH, breast cancer cells, in vivo Received : October 24, 2013 Accepted : November 24, 2013 Published : November 26, 2013 Abstract Cancer cells rely on aerobic glycolysis to maintain cell growth and proliferation via the Warburg effect. Phosphoglycerate dehydrogenase (PHDGH) catalyzes the first step of the serine biosynthetic pathway downstream of glycolysis, which is a metabolic gatekeeper both for macromolecular biosynthesis and serine-dependent DNA synthesis. Here, we report that PHDGH is overexpressed in many ER-negative human breast cancer cell lines. PHGDH knockdown in these cells leads to a reduction of serine synthesis and impairment of cancer cell proliferation. However, PHGDH knockdown does not affect tumor maintenance and growth in established breast cancer xenograft models, suggesting that PHGDH-dependent cancer cell growth may be context-dependent. Our findings suggest that other mechanisms or pathways may bypass exclusive dependence on PHGDH in established human breast cancer xenografts, indicating that PHGDH is dispensable for the growth and maintenance and of tumors in vivo .

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1540

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • PHGDH activity may not be required for proliferation in all PHGDH-amplified cancers; expression has been shown to be dispensable in a breast cancer xenograft model.

    “However, PHGDH activity may not be a requirement for proliferation for all PHGDH-amplified cancers, as expression has been shown to be dispensable in a breast cancer xenograft model (Chen et al., 2013).”

    From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Chen et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Walsh MJ Brimacombe KR Anastasiou D Yu Y Israelsen WJ Hong BS Tempel W Dimov S Veith H Yang H Kung C Yen KE Dang L Salituro F Auld DS Park HW ML265: A potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model Probe Reports from the NIH Molecular Libraries Program. (Bethesda (MD) 2010 23905203

Cited by

Sorted by citations

Authors
Chen, J., Chung, F., Yang, G., Pu, M., Gao, H., Jiang, W., Yin, H., Capka, V., Kasibhatla, S., Laffitte, B., Jaeger, S., Pagliarini, R., Chen, Y., & Zhou, W.
Affiliations
  • Oncology, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States
  • Analytic Science, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, United States
  • Genomics Institute of the Novartis Research Foundation (US)
Venue
Oncotarget
Published
2013-11-26
Volume
4
Issue
12
Pages
2502-2511
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1934493757
Cited by
82
References
27
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 7 · 2021: 16 · 2020: 10 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 13 · 2015: 5 · 2014: 5
FWCI
2.81
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Oncotarget (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
PHGDH, breast cancer, serine biosynthesis, tumor growth, tumor maintenance, aerobic glycolysis, Warburg effect, estrogen receptor-negative breast cancer, xenograft models, tumor cell proliferation
MeSH terms
Animals, Breast Neoplasms, Cell Transformation, Neoplastic, Female, Humans, RNA, Small Interfering, Cell Line, Tumor, Cell Growth Processes, Phosphoglycerate Dehydrogenase, Mice, Gene Knockdown Techniques, MCF-7 Cells, Heterografts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review